<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04149405</url>
  </required_header>
  <id_info>
    <org_study_id>KAEK 2016/100</org_study_id>
    <nct_id>NCT04149405</nct_id>
  </id_info>
  <brief_title>Alterations of GCF Levels of Sclerostin and DKK-1 in Postmenopausal Osteoporosis</brief_title>
  <official_title>Investigation of the Effects of Bisphosphonate on the Gingival Crevicular Fluid Levels of Sclerostin and the DKK-1 in Individuals With Postmenopausal Osteoporosis With Periodontal Changes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ondokuz Mayıs University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ondokuz Mayıs University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Symptoms of periodontal disease are tissue destruction and destruction of the alveolar bone&#xD;
      which supports the tooth. Wnt way (wingless-type MMTV integration site family) plays a role&#xD;
      in the regulation of bone homeostasis in periodontal disease-induced bone resorption. The Wnt&#xD;
      / β-catenin signal is controlled by physiological antagonists, including dickkopf released&#xD;
      from osteocytes-associated protein 1 (DKK-1) and sclerostin (SOST). Thus, Wnt inhibitors SOST&#xD;
      and DKK-1 affect bone mass changes. Bisphosphonates used in osteoporous treatment are&#xD;
      selective inhibitors of bone resorption. In the serum of postmenopausal osteoporotic women&#xD;
      treated with bisphosphonate, short-term and decreased DKK-1 level during the treatment, and&#xD;
      increased SOST in the late period were reported. Increased bone formation after&#xD;
      bisphosphonate treatment in postmenopausal osteoporotic patients has been associated with&#xD;
      increased serum SOST level. The aim of our study is to investigate the effect of&#xD;
      bisphosphonate in patients with post-menopausal osteoporosis on the bone demolition&#xD;
      metabolism in periodontally healthy and periodontally diseased tooth regions and gingival&#xD;
      health with the clinical data by investigating the SOST and DDK-1 molecules that play role in&#xD;
      bone destruction mechanism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to reveal the effect of initial periodontal treatment together with&#xD;
      bisphosphonate on sclerostin (SOST) and dickkopf-related protein-1 (DKK-1) in gingival&#xD;
      crevicular fluid (GCF) of patients with osteoporosis.&#xD;
&#xD;
      Clinical recordings and GCF were obtained from postmenopausal women; with chronic&#xD;
      periodontitis and those using bisphosphonate (Group A, n=12), with chronic periodontitis and&#xD;
      otherwise healthy (Group B, n=10), without chronic periodontitis and those using&#xD;
      bisphosphonate (Group C, n=11), systemically and periodontally healthy controls (Group D,&#xD;
      n=10) at the baseline.&#xD;
&#xD;
      GCF sampling were recorded and repeated at the 6th and 12th months in Group A, B and C. SOST&#xD;
      and DKK-1 values were measured by ELISA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2016</start_date>
  <completion_date type="Actual">December 28, 2018</completion_date>
  <primary_completion_date type="Actual">December 6, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sost Values for 6th Month</measure>
    <time_frame>6 months</time_frame>
    <description>levels of sclerostin in 6th month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dkk-1 Values for 6th Month</measure>
    <time_frame>6 months</time_frame>
    <description>levels of dickkopf-related protein-1 in 6th month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sost Values for 12th Month</measure>
    <time_frame>12 month</time_frame>
    <description>levels of sclerostin in 12th month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dkk-1 Values for 12th Month</measure>
    <time_frame>12 months</time_frame>
    <description>levels of dickkopf-related protein-1 in 12th month</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Osteoporosis, Postmenopausal</condition>
  <condition>Periodontitis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with chronic periodontitis and osteoporosis.&#xD;
Phase 1 periodontal therapy and bisphosphonate therapy ( Aclasta: intravenous infusion of 5 mg of zoledronic acid once a year) were administered to the subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with chronic periodontitis and systemically healthy.&#xD;
Phase 1 periodontal theraphy was administered to the subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with periodontally healthy and osteoporosis.&#xD;
Bisphosphonate therapy ( Aclasta: intravenous infusion of 5 mg of zoledronic acid once a year) were administered to the subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Systemically and periodontally healthy controls&#xD;
No intervention has been made.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Phase 1 periodontal therapy</intervention_name>
    <description>Scaling and root planning with ultrasonic and hand instruments under local anesthesia.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Periodontal treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisphosphonate therapy</intervention_name>
    <description>Using aclasta: intravenous infusion of 5 mg of zoledronic acid once a year</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <other_name>Osteoporosis treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with T scores less than -2.5 (groups A and C)&#xD;
&#xD;
          -  The periodontitis patients were selected based on the radiographical evidence of bone&#xD;
             loss, presence of four or more sites with bleeding on probing (BOP), ≥5 mm pocket&#xD;
             depth (PD) and ≥6 mm clinical attachment loss (CAL).&#xD;
&#xD;
          -  The clinically healthy control groups were selected on the basis of no radiographic&#xD;
             bone loss or CAL and PD≤3 mm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any known systemic disease rather than osteoporosis&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Antibiotic therapy within the last 3 months&#xD;
&#xD;
          -  Periodontal treatment in the last 6 months&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>51 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eser Acarel, PhD,Prof.Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Ondokuz Mayıs University, School of Dentistry, Department of Periodontology</affiliation>
  </overall_official>
  <reference>
    <citation>Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I, Frost ML. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone. 2013 Sep;56(1):42-7. doi: 10.1016/j.bone.2013.05.010. Epub 2013 May 20.</citation>
    <PMID>23702386</PMID>
  </reference>
  <reference>
    <citation>Papapoulos SE, Landman JO, Bijvoet OL, Löwik CW, Valkema R, Pauwels EK, Vermeij P. The use of bisphosphonates in the treatment of osteoporosis. Bone. 1992;13 Suppl 1:S41-9. Review.</citation>
    <PMID>1581119</PMID>
  </reference>
  <reference>
    <citation>Juluri R, Prashanth E, Gopalakrishnan D, Kathariya R, Devanoorkar A, Viswanathan V, Romanos GE. Association of Postmenopausal Osteoporosis and Periodontal Disease: A Double-Blind Case-Control Study. J Int Oral Health. 2015 Sep;7(9):119-23.</citation>
    <PMID>26435630</PMID>
  </reference>
  <results_reference>
    <citation>Lane N, Armitage GC, Loomer P, Hsieh S, Majumdar S, Wang HY, Jeffcoat M, Munoz T. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study. J Periodontol. 2005 Jul;76(7):1113-22.</citation>
    <PMID>16018754</PMID>
  </results_reference>
  <results_reference>
    <citation>Balli U, Aydogdu A, Dede FO, Turer CC, Guven B. Gingival Crevicular Fluid Levels of Sclerostin, Osteoprotegerin, and Receptor Activator of Nuclear Factor-κB Ligand in Periodontitis. J Periodontol. 2015 Dec;86(12):1396-404. doi: 10.1902/jop.2015.150270. Epub 2015 Sep 14.</citation>
    <PMID>26367496</PMID>
  </results_reference>
  <results_reference>
    <citation>Napimoga MH, Nametala C, da Silva FL, Miranda TS, Bossonaro JP, Demasi AP, Duarte PM. Involvement of the Wnt-β-catenin signalling antagonists, sclerostin and dickkopf-related protein 1, in chronic periodontitis. J Clin Periodontol. 2014 Jun;41(6):550-7. doi: 10.1111/jcpe.12245.</citation>
    <PMID>24576302</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 12, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2019</study_first_posted>
  <results_first_submitted>June 23, 2020</results_first_submitted>
  <results_first_submitted_qc>November 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 1, 2020</results_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ondokuz Mayıs University</investigator_affiliation>
    <investigator_full_name>Feyza Otan ÖZDEN</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>sclerostin</keyword>
  <keyword>dickkopf-related protein-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
    <mesh_term>Periodontitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 30, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT04149405/ICF_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT04149405/Prot_SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Postmenopausal women who were admitted to Ondokuz Mayıs University (OMU), Faculty of Medicine, Department of Endocrinology and Metabolism between 2016 and 2018.&#xD;
Patients eligible for the study were directed to OMU, Faculty of Dentistry, Department of Periodontology for periodontal examination after obtaining medical records.</recruitment_details>
      <pre_assignment_details>Smokers and subjects who had received antibiotic treatment in the last 3 months and/or periodontal treatment in the last 6 months were excluded from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A</title>
          <description>subjects with chronic periodontitis and osteoporosis</description>
        </group>
        <group group_id="P2">
          <title>Group B</title>
          <description>subjects with chronic periodontitis and systemically healthy</description>
        </group>
        <group group_id="P3">
          <title>Group C</title>
          <description>subjects with periodontally healthy and osteoporosis</description>
        </group>
        <group group_id="P4">
          <title>Group D</title>
          <description>systemically and periodontally healthy controls</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A</title>
          <description>subjects with chronic periodontitis and osteoporosis</description>
        </group>
        <group group_id="B2">
          <title>Group B</title>
          <description>subjects with chronic periodontitis and systemically healthy</description>
        </group>
        <group group_id="B3">
          <title>Group C</title>
          <description>subjects with periodontally healthy and osteoporosis</description>
        </group>
        <group group_id="B4">
          <title>Group D</title>
          <description>systemically and periodontally healthy controls</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.67" spread="4.77"/>
                    <measurement group_id="B2" value="57.00" spread="4.39"/>
                    <measurement group_id="B3" value="56.45" spread="3.88"/>
                    <measurement group_id="B4" value="56.30" spread="3.91"/>
                    <measurement group_id="B5" value="56.88" spread="4.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>baseline sost values</title>
          <description>initial sclerostin values</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="494.096" spread="99.840"/>
                    <measurement group_id="B2" value="634.731" spread="152.554"/>
                    <measurement group_id="B3" value="1023.071" spread="512.733"/>
                    <measurement group_id="B4" value="2131.87" spread="485.784"/>
                    <measurement group_id="B5" value="1103.417" spread="751.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>baseline dkk-1 levels</title>
          <description>initial dickkopf-related protein-1 values</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1031.323" spread="506.985"/>
                    <measurement group_id="B2" value="1264.632" spread="492.691"/>
                    <measurement group_id="B3" value="2630.430" spread="1679.080"/>
                    <measurement group_id="B4" value="4269.394" spread="1734.732"/>
                    <measurement group_id="B5" value="2358.505" spread="1801.692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sost Values for 6th Month</title>
        <description>levels of sclerostin in 6th month</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>scaling and root planning, bisphosphonate therapy (zoledronic acid)&#xD;
periodontal phase 1 therapy: periodontal phase 1 therapy consisted of scaling and root planning with ultrasonic and hand instruments under local anesthesia.&#xD;
bisphosphonate therapy: bisphosphonate therapy refers to the use of zoledronic acid 5 mg/year (i.v.)&#xD;
GCF: gingival crevicular fluid collection by the same investigator.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>scaling and root planning, no bisphosphonate therapy&#xD;
periodontal phase 1 therapy: periodontal phase 1 therapy consisted of scaling and root planning with ultrasonic and hand instruments under local anesthesia.&#xD;
GCF: gingival crevicular fluid collection by the same investigator.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>bisphosphonate therapy (zoledronic acid)&#xD;
bisphosphonate therapy: bisphosphonate therapy refers to the use of zoledronic acid 5 mg/year (i.v.)&#xD;
GCF: gingival crevicular fluid collection by the same investigator.</description>
          </group>
          <group group_id="O4">
            <title>Group D</title>
            <description>Systemically and periodontally healthy controls No intervention has been made</description>
          </group>
        </group_list>
        <measure>
          <title>Sost Values for 6th Month</title>
          <description>levels of sclerostin in 6th month</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1389.177" spread="670.834"/>
                    <measurement group_id="O2" value="1085.405" spread="618.136"/>
                    <measurement group_id="O3" value="1596.585" spread="841.026"/>
                    <measurement group_id="O4" value="2131.87" spread="485.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Kruskal-Wallis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.01</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dkk-1 Values for 6th Month</title>
        <description>levels of dickkopf-related protein-1 in 6th month</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Subjects with chronic periodontitis and osteoporosis.&#xD;
Phase 1 periodontal therapy and bisphosphonate therapy ( Aclasta: intravenous infusion of 5 mg of zoledronic acid once a year) were administered to the subjects.&#xD;
Phase 1 periodontal therapy: Scaling and root planning with ultrasonic and hand instruments under local anesthesia.&#xD;
Bisphosphonate therapy: Using aclasta: intravenous infusion of 5 mg of zoledronic acid once a year</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Subjects with chronic periodontitis and systemically healthy.&#xD;
Phase 1 periodontal theraphy was administered to the subjects.&#xD;
Phase 1 periodontal therapy: Scaling and root planning with ultrasonic and hand instruments under local anesthesia.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Subjects with periodontally healthy and osteoporosis.&#xD;
Bisphosphonate therapy ( Aclasta: intravenous infusion of 5 mg of zoledronic acid once a year) were administered to the subjects.&#xD;
Bisphosphonate therapy: Using aclasta: intravenous infusion of 5 mg of zoledronic acid once a year</description>
          </group>
          <group group_id="O4">
            <title>Group D</title>
            <description>Systemically and periodontally healthy controls No intervention has been made</description>
          </group>
        </group_list>
        <measure>
          <title>Dkk-1 Values for 6th Month</title>
          <description>levels of dickkopf-related protein-1 in 6th month</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3358.265" spread="1477.199"/>
                    <measurement group_id="O2" value="1963.185" spread="966.451"/>
                    <measurement group_id="O3" value="3263.665" spread="2298.590"/>
                    <measurement group_id="O4" value="4269.39" spread="1734.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sost Values for 12th Month</title>
        <description>levels of sclerostin in 12th month</description>
        <time_frame>12 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Subjects with chronic periodontitis and osteoporosis.&#xD;
Phase 1 periodontal therapy and bisphosphonate therapy ( Aclasta: intravenous infusion of 5 mg of zoledronic acid once a year) were administered to the subjects.&#xD;
Phase 1 periodontal therapy: Scaling and root planning with ultrasonic and hand instruments under local anesthesia.&#xD;
Bisphosphonate therapy: Using aclasta: intravenous infusion of 5 mg of zoledronic acid once a year</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Subjects with chronic periodontitis and systemically healthy.&#xD;
Phase 1 periodontal theraphy was administered to the subjects.&#xD;
Phase 1 periodontal therapy: Scaling and root planning with ultrasonic and hand instruments under local anesthesia.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Subjects with periodontally healthy and osteoporosis.&#xD;
Bisphosphonate therapy ( Aclasta: intravenous infusion of 5 mg of zoledronic acid once a year) were administered to the subjects.&#xD;
Bisphosphonate therapy: Using aclasta: intravenous infusion of 5 mg of zoledronic acid once a year</description>
          </group>
          <group group_id="O4">
            <title>Group D</title>
            <description>Systemically and periodontally healthy controls No intervention has been made</description>
          </group>
        </group_list>
        <measure>
          <title>Sost Values for 12th Month</title>
          <description>levels of sclerostin in 12th month</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1702.265" spread="1012.124"/>
                    <measurement group_id="O2" value="1347.330" spread="876.383"/>
                    <measurement group_id="O3" value="1114.988" spread="368.840"/>
                    <measurement group_id="O4" value="2131.87" spread="485.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dkk-1 Values for 12th Month</title>
        <description>levels of dickkopf-related protein-1 in 12th month</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>-Subjects with chronic periodontitis and osteoporosis.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>-Subjects with chronic periodontitis and systemically healthy.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>-Subjects with periodontally healthy and osteoporosis.</description>
          </group>
          <group group_id="O4">
            <title>Group D</title>
            <description>Systemically and periodontally healthy controls No intervention has been made</description>
          </group>
        </group_list>
        <measure>
          <title>Dkk-1 Values for 12th Month</title>
          <description>levels of dickkopf-related protein-1 in 12th month</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3440.67" spread="2347.112"/>
                    <measurement group_id="O2" value="3203.802" spread="1706.081"/>
                    <measurement group_id="O3" value="2490.553" spread="841.512"/>
                    <measurement group_id="O4" value="4269.39" spread="1734.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were not monitored/assessed</time_frame>
      <desc>All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed in any participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group A</title>
          <description>Participants received periodontal phase 1 treatment and used bisphosphonate.</description>
        </group>
        <group group_id="E2">
          <title>Group B</title>
          <description>Participants received periodontal phase 1 treatment.</description>
        </group>
        <group group_id="E3">
          <title>Group C</title>
          <description>Participants used bisphosphonate.</description>
        </group>
        <group group_id="E4">
          <title>Group D</title>
          <description>Participants did not receive any treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Feyza Otan Özden</name_or_title>
      <organization>OndokusMU</organization>
      <phone>+905322535106</phone>
      <email>feyza_otan@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

